Sex Differences in Recovery from Postoperative Sarcopenia During Adjuvant CAPOX Therapy for Colorectal Cancer

Overview

Journal J Cancer Res Clin Oncol

Specialty Oncology

Date 2024 Oct 26

PMID 39460854

Authors

Hiroaki Nozawa

Shinya Abe

Kentaro Abe

Yumi Yokota

Shunsuke Hori

Mitsutaka Yakabe

Kazuhito Sasaki

Shigenobu Emoto

Yuichiro Yokoyama

Hirofumi Sonoda

Koji Murono

Hiroyuki Matsuzaki

Yuzo Nagai

Takahide Shinagawa

Masahiro Akishita

Soichiro Ishihara

Affiliations

Soon will be listed here.

Abstract

Background: Women are predisposed to develop intolerance to cancer chemotherapy. Sarcopenia and chemotherapy are mutually related. Women are generally intolerable to chemotherapeutics such as 5-fluorouracil. Although adjuvant oxaliplatin-based chemotherapy, e.g. CAPOX is commonly used to treat colorectal cancer, its effects on patients in terms of sarcopenia and sex remain unknown. We investigated sex disparities in the impacts of CAPOX on body composition in this study.

Methods: We conducted a prospective study on diagnostic metrics used for sarcopenia in colorectal cancer patients receiving adjuvant CAPOX. Evaluations of the nutritional status by the Mini-Nutritional Assessment (MNA), gait speed, grip strength, skeletal muscle mass, fat mass, and bone mineral content using a body composition analyzer were performed in the first, fourth, and eighth cycles of CAPOX (first, second, and third measurements, respectively).

Results: Among 80 eligible patients, 61 completed four CAPOX cycles. The median differences in MNA, gait, grip strength, muscle mass, fat mass, and bone mineral content between the first and second measurements for men (n = 35) and women (n = 26) were + 10.5% and + 2.9% (p = 0.067), + 4.5% and - 2.6% (p = 0.16), + 1.8% and + 2.8% (p = 0.66), + 2.7% and + 1.3% (p = 0.021), + 4.5% and + 3.5% (p = 0.59), and + 3.3% and + 0.0% (p = 0.006), There were no sex differences in comparisons of the above metrics between the first and third measurements in 34 patients who completed eight CAPOX cycles (19 wen and 15 women).

Conclusions: Early cycles of adjuvant CAPOX may have a negative impact on the postoperative recovery of several metrics for diagnosing sarcopenia in women.

References

De Francia S, Berchialla P, Armando T, Storto S, Allegra S, Sciannameo V . Colorectal cancer chemotherapy: can sex-specific disparities impact on drug toxicities?. Eur J Clin Pharmacol. 2022; 78(6):1029-1038. PMC: 9107437. DOI: 10.1007/s00228-022-03298-y. View

Land S, Kopec J, Cecchini R, Ganz P, Wieand H, Colangelo L . Neurotoxicity from oxaliplatin combined with weekly bolus fluorouracil and leucovorin as surgical adjuvant chemotherapy for stage II and III colon cancer: NSABP C-07. J Clin Oncol. 2007; 25(16):2205-11. DOI: 10.1200/JCO.2006.08.6652. View

Yamaoka Y, Fujitani K, Tsujinaka T, Yamamoto K, Hirao M, Sekimoto M . Skeletal muscle loss after total gastrectomy, exacerbated by adjuvant chemotherapy. Gastric Cancer. 2014; 18(2):382-9. DOI: 10.1007/s10120-014-0365-z. View

Hardy E, Hatt J, Doleman B, Smart T, Piasecki M, Lund J . Post-operative electrical muscle stimulation attenuates loss of muscle mass and function following major abdominal surgery in older adults: a split body randomised control trial. Age Ageing. 2022; 51(10). PMC: 9621149. DOI: 10.1093/ageing/afac234. View

Tisdale M . Mechanisms of cancer cachexia. Physiol Rev. 2009; 89(2):381-410. DOI: 10.1152/physrev.00016.2008. View

Andre T, Boni C, Mounedji-Boudiaf L, Navarro M, Tabernero J, Hickish T . Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer. N Engl J Med. 2004; 350(23):2343-51. DOI: 10.1056/NEJMoa032709. View

Andre T, Meyerhardt J, Iveson T, Sobrero A, Yoshino T, Souglakos I . Effect of duration of adjuvant chemotherapy for patients with stage III colon cancer (IDEA collaboration): final results from a prospective, pooled analysis of six randomised, phase 3 trials. Lancet Oncol. 2020; 21(12):1620-1629. PMC: 7786835. DOI: 10.1016/S1470-2045(20)30527-1. View

Wagner A, Grothey A, Andre T, Dixon J, Wolmark N, Haller D . Sex and Adverse Events of Adjuvant Chemotherapy in Colon Cancer: An Analysis of 34 640 Patients in the ACCENT Database. J Natl Cancer Inst. 2020; 113(4):400-407. PMC: 8023830. DOI: 10.1093/jnci/djaa124. View

Haller D, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E . Capecitabine plus oxaliplatin compared with fluorouracil and folinic acid as adjuvant therapy for stage III colon cancer. J Clin Oncol. 2011; 29(11):1465-71. DOI: 10.1200/JCO.2010.33.6297. View

10.

Blauwhoff-Buskermolen S, Versteeg K, de van der Schueren M, den Braver N, Berkhof J, Langius J . Loss of Muscle Mass During Chemotherapy Is Predictive for Poor Survival of Patients With Metastatic Colorectal Cancer. J Clin Oncol. 2016; 34(12):1339-44. DOI: 10.1200/JCO.2015.63.6043. View

11.

Chen L, Woo J, Assantachai P, Auyeung T, Chou M, Iijima K . Asian Working Group for Sarcopenia: 2019 Consensus Update on Sarcopenia Diagnosis and Treatment. J Am Med Dir Assoc. 2020; 21(3):300-307.e2. DOI: 10.1016/j.jamda.2019.12.012. View

12.

Guigoz Y . The Mini Nutritional Assessment (MNA) review of the literature--What does it tell us?. J Nutr Health Aging. 2006; 10(6):466-85. View

13.

Arribas L, Sabate-Llobera A, Domingo M, Taberna M, Sospedra M, Martin L . Assessing dynamic change in muscle during treatment of patients with cancer: Precision testing standards. Clin Nutr. 2022; 41(5):1059-1065. DOI: 10.1016/j.clnu.2022.03.016. View

14.

Dekker E, Tanis P, Vleugels J, Kasi P, Wallace M . Colorectal cancer. Lancet. 2019; 394(10207):1467-1480. DOI: 10.1016/S0140-6736(19)32319-0. View

15.

Cuervo M, Garcia A, Ansorena D, Sanchez-Villegas A, Martinez-Gonzalez M, Astiasaran I . Nutritional assessment interpretation on 22,007 Spanish community-dwelling elders through the Mini Nutritional Assessment test. Public Health Nutr. 2008; 12(1):82-90. DOI: 10.1017/S136898000800195X. View

16.

Antoun S, Bayar M, Dyevre V, Lanoy E, Smolenschi C, Ducreux M . No evidence for changes in skeletal muscle mass or weight during first-line chemotherapy for metastatic colorectal cancer. BMC Cancer. 2019; 19(1):847. PMC: 6714393. DOI: 10.1186/s12885-019-6086-2. View

17.

Schmoll H, Tabernero J, Maroun J, De Braud F, Price T, Van Cutsem E . Capecitabine Plus Oxaliplatin Compared With Fluorouracil/Folinic Acid As Adjuvant Therapy for Stage III Colon Cancer: Final Results of the NO16968 Randomized Controlled Phase III Trial. J Clin Oncol. 2015; 33(32):3733-40. DOI: 10.1200/JCO.2015.60.9107. View

18.

Miyamoto Y, Baba Y, Sakamoto Y, Ohuchi M, Tokunaga R, Kurashige J . Negative Impact of Skeletal Muscle Loss after Systemic Chemotherapy in Patients with Unresectable Colorectal Cancer. PLoS One. 2015; 10(6):e0129742. PMC: 4466562. DOI: 10.1371/journal.pone.0129742. View

19.

Brown J, Ellis S, Silcocks P, Blumsohn A, Gutcher S, Radstone C . Effect of chemotherapy on skeletal health in male survivors from testicular cancer and lymphoma. Clin Cancer Res. 2006; 12(21):6480-6. DOI: 10.1158/1078-0432.CCR-06-1382. View

20.

Yoshino T, Argiles G, Oki E, Martinelli E, Taniguchi H, Arnold D . Pan-Asian adapted ESMO Clinical Practice Guidelines for the diagnosis treatment and follow-up of patients with localised colon cancer. Ann Oncol. 2021; 32(12):1496-1510. DOI: 10.1016/j.annonc.2021.08.1752. View